Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cross-reactivity

Cross-reactivity

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma.

Journal for immunotherapy of cancer·2026

Same author

Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and Complications.

Clinical and translational gastroenterology·2026

Same author

Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Cancer discovery·2026

Same author

Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma.

Melanoma research·2026

Same author

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

Cancer cell·2026

Same author

Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Combination immunotherapy: a road map.

Patrick A Ott¹, F Stephen Hodi¹, Howard L Kaufman²

¹Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Dana540C, Boston, MA 02215 USA.

Journal for Immunotherapy of Cancer

|February 28, 2017

Summary

Cancer immunotherapy using PD-1/PD-L1 inhibitors shows promise but requires combinations for broader efficacy. The Society for Immunotherapy of Cancer (SITC) task force explored challenges and strategies for combination immunotherapy development.

Keywords:

Checkpoint inhibitors Clinical trial Combination Endpoints Immunotherapy Preclinical models

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 7, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Cancer immunotherapy, particularly monoclonal antibodies targeting the PD-1/PD-L1 pathway, has significantly advanced cancer treatment.
Despite successes, many patients do not respond to PD-1/PD-L1 pathway inhibitors alone, necessitating combination strategies.
Combining PD-1/PD-L1 inhibitors with other agents may enhance clinical benefits, as suggested by early studies in melanoma and NSCLC.

Purpose of the Study:

To address progress and challenges in cancer combination immunotherapy.
To identify and prioritize promising combination strategies involving PD-1 pathway inhibitors.
To provide an overview of current evidence and discuss key developmental issues.

Main Methods:

Convening a Combination Immunotherapy Task Force by the Society for Immunotherapy of Cancer (SITC).
Reviewing current evidence for PD-1 pathway inhibitors as a backbone in combination therapies.
Discussing critical aspects of combination immunotherapy development, including preclinical modeling, safety, trial design, and endpoints.

Main Results:

PD-1 pathway inhibitors show potential as a backbone for combination immunotherapy due to clinical benefits and tolerable side effects.
The SITC task force identified key challenges in developing combination immunotherapies.
The manuscript summarizes the current status and future challenges for combination immunotherapy.

Conclusions:

Combination immunotherapy holds significant promise for improving cancer treatment outcomes.
Addressing challenges in preclinical modeling, patient safety, and clinical trial design is crucial for successful development.
Further research and strategic development are needed to optimize combination immunotherapy approaches for a wider patient population.